Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead's Kite has announced the acquisition of Tmunity Therapeutics, enhancing its CAR T-therapy capabilities. This strategic move will add pipeline assets and access to innovative research through a partnership with the University of Pennsylvania. Tmunity's armored CAR T technology may improve anti-tumor activity, and Kite will now manage ongoing research collaborations with Penn. The financial terms remain undisclosed, but the deal is forecast to reduce Gilead's 2023 EPS by approximately $0.18-$0.22. The acquisition is expected to close in Q1 2023, pending regulatory approvals.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) reported positive interim results from the ARC-7 study, a Phase 2 trial in patients with first-line metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Both doublet and triplet therapy arms containing domvanalimab showed a 35-45% reduction in the risk of progression or death compared to zimberelimab monotherapy, with median progression-free survival (PFS) of 12.0 months for the doublet and 10.9 months for the triplet. Results will be showcased on December 20 during the ASCO Monthly Plenary Series.
Gilead Sciences and Arcus Biosciences reported promising results from the ARC-7 Study, focusing on first-line, metastatic non-small cell lung cancer (NSCLC). The study demonstrated a 35-45% reduction in the risk of progression or death and a significant improvement in median progression-free survival (PFS) with the combination therapies compared to zimberelimab monotherapy. The objective response rates showed a positive trend, with the doublet and triplet arms showing 41% and 40%, respectively. Further detailed results will be presented on December 20.
Gilead Sciences has announced its support for Latinas Contra Cancer, a nonprofit focused on advocating for improved cancer care in the Latinx community. Executive Director Darcie Green highlights the challenges faced in navigating healthcare systems, drawing from her personal experience. The organization has launched the Defensoras: Healthcare Advocate Training program, empowering cancer patients to advocate for their rights. This initiative aims to address racial and ethnic disparities in healthcare, ultimately enhancing patient knowledge and support.
Summary not available.
Kite, a Gilead Company (Nasdaq: GILD), presented follow-up analyses from pivotal studies ZUMA-2 and ZUMA-3 on CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and mantle cell lymphoma (MCL). Findings revealed significant overall survival advantages, with Tecartus showing improved two-year outcomes compared to standard care. Tecartus is the first CAR T-cell therapy approved for adults with these conditions. Presentations took place at the 2022 ASH Annual Meeting on December 10 and 12.
Kite, a Gilead Company (Nasdaq: GILD), announced significant three-year follow-up data from the ZUMA-5 study for Yescarta (axicabtagene ciloleucel), showing sustained response in 52% of patients with relapsed or refractory indolent non-Hodgkin lymphoma. The study reported an overall response rate (ORR) of 90% and a complete response (CR) rate of 75% among 159 patients. Additionally, ZUMA-1 data highlighted the benefits of prophylactic corticosteroids in managing patient safety without compromising treatment outcomes. Yescarta remains a pivotal therapy in treating difficult lymphomas.
Kite, a Gilead Company (Nasdaq: GILD), announced outcomes from two analyses of the ZUMA-7 trial for Yescarta, a CAR T-cell therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). Findings reveal 47% of patients needing subsequent therapy after second-line Yescarta compared to 71% for standard care. The study affirmed Yescarta's superiority in event-free survival (EFS) and progression-free survival (PFS), particularly for patients with varying metabolic tumor volumes. Yescarta's FDA approval in April 2022 and EMA's in October 2022 continue to underline its pivotal role in lymphoma treatment.
Kite, a Gilead company (Nasdaq: GILD), reported significant findings from a real-world analysis of Yescarta (axicabtagene ciloleucel) in treating relapsed or refractory large B-cell lymphoma (LBCL). The median 'vein-to-vein' time was 27 days, with a manufacturing time of 7 days and a total turnaround of 16 days. Shorter treatment times correlated with a 60% complete response rate. The analysis included 1,383 patients from 78 treatment centers. Data was presented at the 2022 ASH Annual Meeting.
Kite and Arcellx have announced a global collaboration to co-develop the CART-ddBCMA therapy for relapsed or refractory multiple myeloma. Kite will provide an upfront payment of $225 million and a $100 million equity investment. The companies will share development and commercialization costs, splitting U.S. profits 50/50. The partnership aims to address the significant unmet need in multiple myeloma treatment.
The transaction is expected to close in Q1 2023 and may reduce Gilead's EPS by approximately $0.16. The collaboration capitalizes on Kite's leadership in cell therapy and Arcellx's innovative approach.